LeMaitre Vascular (NasdaqGM:LMAT) in our automated value investing analysis, with the cash flow history and price comparison below.
Advertisement helps keep Trendshare free for most readers.
Estimate how long you need to hold LeMaitre Vascular to reach your target.
Based on historical returns, we believe that LeMaitre Vascular can grow its free cash at a rate of about 8%. That's positive!
| Advantages | Disadvantages |
|---|---|
|
|
| LMAT Price (LeMaitre Vascular stock price per share) |
$73.61 | |
|
|
LMAT Fair Price (based on intrinsic value) |
$17.20 |
| LMAT Safety Price (based on a variable margin of safety) | $10.32 | |
|
Try your own return
The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value. Value per share: |
||
| PE Ratio versus Sector | 35% higher than other Healthcare stocks | |
| PE Ratio versus Industry | 63% higher than other Medical Devices stocks | |
| Free Cash Flow Jitter | 52% | |
| Dividend Yield | 1.27% (tax impact) | Shares Shorted | 1,656,867 |
No open-market insider buys or sells are recorded in the six months to 2026-11-21.
The six months before that had 0 buys and 7 sales.
Open-market buys and sells reported by LeMaitre Vascular's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-08 | LeMaitre George W (Chairman and CEO) | Sell | 27,881 | $108.69 |
| 2026-05-08 | Kamke Trent G (Senior V. P., Operations) | Sell | 2,928 | $107.00 |
| 2026-05-07 | Jasinski Lawrence J | Sell | 3,943 | $110.00 |
| 2026-05-07 | Ross Bridget A | Sell | 5,044 | $111.10 |
| 2026-05-07 | LeMaitre George W (Chairman and CEO) | Sell | 18,600 | $107.64 |
| 2026-03-11 | Kamke Trent G (Senior V. P., Operations) | Sell | 2,625 | $108.50 |
| 2026-03-11 | Roberts David B (President and Director) | Sell | 3,311.68 | $107.68 |
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 1,656,867 shares shorted. With 21,307,125 shares available for purchase and an average trading volume over the past 10 trading days of 226,740, it would take at least 7.3 days for all of the short holders to cover their shorts.
Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth
How to read this: free cash flow in plain terms, free cash flow jitter.
Each year names the SEC filer that reported it, so a change of filer shows up here.
| Fiscal year | SEC filer (CIK) | Free cash flow (USD millions) |
|---|---|---|
| 2009 | 1158895 | 4.9 |
| 2010 | 1158895 | 5.5 |
| 2011 | 1158895 | 1.5 |
| 2012 | 1158895 | 3.2 |
| 2013 | 1158895 | 3.6 |
| 2014 | 1158895 | 3.6 |
| 2015 | 1158895 | 9.6 |
| 2016 | 1158895 | 14.8 |
| 2017 | 1158895 | 19.8 |
| 2018 | 1158895 | 16.4 |
| 2019 | 1158895 | 10.5 |
| 2020 | 1158895 | 31 |
| 2021 | 1158895 | 30.9 |
| 2022 | 1158895 | 21.8 |
| 2023 | 1158895 | 32.3 |
| 2024 | 1158895 | 39.1 |
| 2025 | 1158895 | 75.4 |
Download the yearly data as CSV.
How to read this: what free cash flow is, why earnings matter.
Over the 17 fiscal years from 2009 to 2025 with positive net income, operating cash flow totaled $374 million against net income of $296 million, or 1.26 times.
In 2025, operating cash flow was 1.41 times net income, compared with 1.61 times for the earliest three years (2009 to 2011).
In 2025, capital expenditures were $6.8 million, 8.3% of operating cash flow of $81.3 million, which leaves an estimated $74.5 million after capex. Across the 17 years with reported capex, it averaged 16.2% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.
| Fiscal year | Net income (USD millions) | Operating cash flow (USD millions) | Capital expenditures (USD millions) | Operating cash flow / net income |
|---|---|---|---|---|
| 2009 | 1.6 | 5.4 | 0.6 | 3.40 |
| 2010 | 6 | 7.1 | 2.5 | 1.17 |
| 2011 | 2.1 | 3.2 | 2 | 1.48 |
| 2012 | 2.6 | 4.7 | 1.2 | 1.84 |
| 2013 | 3.2 | 5.4 | 2.7 | 1.68 |
| 2014 | 3.9 | 5.5 | 1.2 | 1.41 |
| 2015 | 7.8 | 11.4 | 2.3 | 1.47 |
| 2016 | 10.6 | 16.9 | 2.8 | 1.60 |
| 2017 | 17.2 | 22.9 | 6.4 | 1.33 |
| 2018 | 22.9 | 19.5 | 3.1 | 0.85 |
| 2019 | 17.9 | 14.2 | 3.8 | 0.79 |
| 2020 | 21.2 | 34.8 | 3 | 1.64 |
| 2021 | 26.9 | 35.1 | 4.9 | 1.30 |
| 2022 | 20.6 | 25.4 | 3.2 | 1.23 |
| 2023 | 30.1 | 36.8 | 7.3 | 1.22 |
| 2024 | 44 | 44.1 | 7 | 1.00 |
| 2025 | 57.7 | 81.3 | 6.8 | 1.41 |
How to read this: why companies buy back shares, dividend yield explained.
Over the 10 fiscal years from 2016 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $292 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.
In the 10 of those years with dividend payment facts, dividends paid totaled $92.6 million, 31.7% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 10 of those 10 years.
In 1 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $0.7 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.
In 2025, dividends paid were $18.1 million, 24.0% of estimated free cash flow of $75.4 million.
| Fiscal year | Estimated free cash flow (USD millions) | Dividends paid (USD millions) | Cash spent repurchasing shares (USD millions) | Total returned (USD millions) | Total as a percent of estimated free cash flow |
|---|---|---|---|---|---|
| 2016 | 14.8 | 3.3 | 0.3 | 3.6 | 24.5% |
| 2017 | 19.8 | 4.2 | 0.8 | 5 | 25.1% |
| 2018 | 16.4 | 5.4 | 0.7 | 6.2 | 37.8% |
| 2019 | 10.5 | 6.7 | 0.7 | 7.4 | 70.6% |
| 2020 | 31 | 7.7 | 0.6 | 8.3 | 26.7% |
| 2021 | 30.9 | 9.3 | 0.8 | 10.1 | 32.8% |
| 2022 | 21.8 | 11 | 0.6 | 11.6 | 53.4% |
| 2023 | 32.3 | 12.4 | 0.9 | 13.3 | 41.1% |
| 2024 | 39.1 | 14.4 | 1.7 | 16.1 | 41.2% |
| 2025 | 75.4 | 18.1 | 1.8 | 19.9 | 26.4% |
Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.
How to read this: earnings and margins.
Revenue was $50.9 million in 2009 and $250 million in 2025, a compound annual growth rate of 10.4% over 16 years.
Revenue rose 13.5% from 2024 to 2025.
Our estimated free cash flow was $75.4 million in 2025, 30.2% of revenue. In 2009 the estimated margin was 9.6%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.
| Fiscal year | Revenue (USD millions) | Estimated free cash flow (USD millions) | Estimated free cash flow / revenue |
|---|---|---|---|
| 2009 | 50.9 | 4.9 | 9.6% |
| 2010 | 56.1 | 5.5 | 9.9% |
| 2011 | 57.7 | 1.5 | 2.6% |
| 2012 | 56.7 | 3.2 | 5.6% |
| 2013 | 64.5 | 3.6 | 5.6% |
| 2014 | 71.1 | 3.6 | 5.1% |
| 2015 | 78.4 | 9.6 | 12.2% |
| 2016 | 89.2 | 14.8 | 16.7% |
| 2017 | 101 | 19.8 | 19.6% |
| 2018 | 106 | 16.4 | 15.5% |
| 2019 | 117 | 10.5 | 9.0% |
| 2020 | 129 | 31 | 24.0% |
| 2021 | 154 | 30.9 | 20.0% |
| 2022 | 162 | 21.8 | 13.5% |
| 2023 | 193 | 32.3 | 16.7% |
| 2024 | 220 | 39.1 | 17.8% |
| 2025 | 250 | 75.4 | 30.2% |
How to read this: how debt and assets are compared, the current ratio.
In 2025, cash and equivalents were $28.2 million against total liabilities of $222 million, or 12.7% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.
Total liabilities were 36.1% of total assets in 2025, compared with 17.3% in 2010, an increase of 18.8 percentage points.
Stockholders equity was $394 million in 2025, compared with $52.4 million in 2010, a rise of 651.6%.
Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 13.7% in 2025. Invested capital here is total assets less cash and current liabilities.
| Fiscal year | Total assets (USD millions) | Cash and equivalents (USD millions) | Total liabilities (USD millions) | Stockholders equity (USD millions) |
|---|---|---|---|---|
| 2010 | 63.3 | 22.6 | 10.9 | 52.4 |
| 2011 | 59.7 | 20.1 | 7.6 | 52.1 |
| 2012 | 63.1 | 16.4 | 10.2 | 52.9 |
| 2013 | 70.5 | 14.7 | 13.9 | 56.6 |
| 2014 | 81.5 | 18.7 | 13.3 | 68.2 |
| 2015 | 90.7 | 27.5 | 12.8 | 77.9 |
| 2016 | 102 | 24.3 | 14.4 | 87.5 |
| 2017 | 126 | 19.1 | 16.6 | 110 |
| 2018 | 153 | 26.3 | 22.9 | 130 |
| 2019 | 188 | 11.8 | 40.2 | 148 |
| 2020 | 253 | 26.8 | 80.2 | 173 |
| 2021 | 293 | 13.9 | 38.7 | 254 |
| 2022 | 310 | 19.1 | 42.3 | 268 |
| 2023 | 347 | 24.3 | 48.9 | 298 |
| 2024 | 552 | 25.6 | 215 | 337 |
| 2025 | 616 | 28.2 | 222 | 394 |
Every one of the 17 fiscal years we have for LeMaitre Vascular under its current filer shows positive free cash flow.
At $73.61, LeMaitre Vascular trades above our fair value estimate of $17.20.
Free cash flow from the first three years of data averaged $4 million, and from the last three $48.9 million: a sharp rise.
Year-to-year variability in free cash flow is volatile, measured at 52%.
Its dividend yield is 1.27%.
Our value investing guide explains how to test these numbers against the filings themselves.
How to read this: the price to earnings ratio.
Its trailing P/E ratio is 35% above the average for stocks in the Healthcare sector.
Its trailing P/E ratio is 63% above the average for stocks in the Medical Devices industry.
A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.
These are companies in the Medical Devices industry, the ones closest in market capitalization to LeMaitre Vascular, limited to companies whose pages we publish. The figures come from our latest data for each company.
| Company | Market cap (USD millions) | P/E | Dividend yield | Cash yield | Price versus our estimate |
|---|---|---|---|---|---|
| LeMaitre Vascular (LMAT) | 1,684 | 27.1 | 1.3% | - | 328% above |
| CONMED Corporation (CNMD) | 1,382 | 19.2 | - | 5.6% | 35% below |
| UFP Technologies (UFPT) | 2,253 | 29.7 | - | 0.1% | 395% above |
| IRadimed Corporation (IRMD) | 1,036 | 43.3 | 1.0% | - | 995% above |
| Tactile Systems Technology (TCMD) | 573 | 24.9 | - | - | 162% above |
| InfuSystem Holdings (INFU) | 287 | 32.6 | - | - | 402% above |
| Utah Medical Products (UTMD) | 198 | 20.8 | 1.7% | 6.7% | 75% below |
Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.
Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.
Every fiscal year on this page is reported by one SEC filer, CIK 1158895.
Each figure on this page comes from that filer.
How to read this: understanding investment risk.
Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.
Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.
The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.
This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.
Read the filings yourself: LMAT annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.
Advertisement supports free stock analysis content.
Does LeMaitre Vascular have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
This example shows how we apply the Trendshare checklist to LMAT: earnings power, cash generation, valuation, and margin of safety.
We check: business quality, free cash flow, P/E, and margin of safety.
Most Popular Articles
How Does Portfolio Churning Affect Your Returns?
Insider Buying as a Conviction Signal
What is Market Capitalization?
What is Cash Return on Invested Capital?